Request Demo
Insilico teams up with Menarini for breast cancer KAT6 inhibitor
Phase 1License out/in
The standard of care for ER+/HER2- breast cancers is endocrine treatments, that may eventually stop working. Credit: Anchiy via Getty Images.
Insilico Medicine has joiER+/HER2- breast cancers through its subsidiary Stemline Therapeutics to develop a small molecule KAT6A inhibitor to treat hormone-sensitive cancers, focusing on ER+/HER2- breast cancer.
Insilico Medicine involves an exclusive lMenariniMenarini agreement, providing StStemline Therapeuticsghts to develop and commerciaKAT6A inhibitorKAT6Aa novel KAT6A inhibihormone-sensitive cancersing Insilico’sER+/HER2- breast cancere (AI) platform.
The molecule has shown positive results in preclinical studies, demonstStemline potent inhibition in multiple CDX and PDX models, as welKAT6A inhibitorKAT6Aa good safety and efficacy profile. Insilico presented data on this development at the San Antonio Breast Cancer Symposium last month.
Insilico will receive $12m in an upfront payment from Menarini, as well as milestone payments with a combined value of more than $500m and sales royalties.Breast Cancer
In the announcementInsiliconying the agreement, Menarini CEO Elcin Barker Ergun said: “Having brought the first innovaWuXi AppTecocrine therapy after almost 20 years to the US and Europe with elacestrant for ER+/HER2- breast cancer patients, our aim is to further augment patient outcomes, and targeting KAT6A can potentially serve that in breast cancer and beyond.”
KAT6A proteins play a crucial role in regulatingMenarinipression and are implicated in various cancers, including poor clinical outcomes of ER+/HER- breast cancers.elacestrantER+/HER2- breast cancerKAT6Abreast cancer
Other companies are also looking at the same protein inhibition. Pfizer’s PF-07248144 is under cancersment for the treatment of locally advaER+/HER- breast cancersHER2- breast cancer, metastatic castration-resistant prostate cancer and metastatic non-small cell lung cancer (NSCLC).
According to GlobalData’s Pharmaceutical Intelligence Center, PF-Pfizer44 PF-07248144y being investigated in a Phase I clinical trial, with a Phase II trial plER+/HER2- breast cancermetastatic castration-resistant prostate cancermetastatic non-small cell lung cancer (NSCLC)
GlobalData is the parent company of Pharmaceutical Technology.PF-07248144
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.